Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer
Authors:
Open Access
- 7 October 2010
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 536
Abstract
Background: The mammalian target of rapamycin (mTOR) plays a key role in cellular growth and homeostasis. The purpose of our present study is to investigate the expression of activated mTOR (p-mTOR) in gastric cancer patients, their prognostic significance and the inhibition effect of RAD001 on tumor growth and to determine whether targeted inhibition of mTOR could be a potential therapeutic strategy for gastric cancer. Methods: The expression of p-mTOR was detected in specimens of 181 gastric cancers who underwent radical resection (R0) by immunohistochemistry. The correlation of p-mTOR expression to clinicopathologic features and survival of gastric cancer was studied. We also determined the inhibition effect of RAD001 on tumor growth using BGC823 and AGS human gastric cancer cell lines. Results: Immunostaining for p-mTOR was positive in 93 of 181 (51.4%) gastric cancers, closely correlated with lymph node status and pTNM stage. Patients with p-mTOR positive showed significantly shorter disease-free survival (DFS) and overall survival (OS) rates than those with p-mTOR-negative tumors in univariable analyses, and there was a trend toward a correlation between p-mTOR expression and survival in multivariable analyses. RAD001 markedly inhibited dose-dependently proliferation of human gastric carcinoma cells by down-regulating expression of p70s6k, p-p70s6k, C-myc, CyclinD1 and Bcl-2, up-regulating expression of P53. Conclusions: In gastric cancer, p-mTOR is a potential therapeutic target and RAD001 was a promising treatment agent with inducing cell cycle arrest and apoptosis by down-regulating expression of C-myc, CyclinD1 and Bcl-2, up-regulating expression of P53.Keywords
This publication has 32 references indexed in Scilit:
- Clinicopathologic significance of HIF-1α, p53, and VEGF expression and preoperative serum VEGF level in gastric cancerBMC Cancer, 2008
- Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapyMolecular Carcinogenesis, 2007
- Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer PatientsAnnals of Surgical Oncology, 2007
- Activated Mammalian Target of Rapamycin Is an Adverse Prognostic Factor in Patients with Biliary Tract AdenocarcinomaClinical Cancer Research, 2007
- Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative SurgeryWorld Journal of Surgery, 2007
- Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental modelInternational Journal of Cancer, 2007
- Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomasCancer, 2007
- mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rateJournal of Surgical Oncology, 2006